GRIA2 and glaucoma: Restoring the ADAR-based RNA processing machinery may be a novel target for the prevention and treatment of glaucoma, which was verified by genomic editing of the GluA2 Q/R site in retinal ganglion cells (Sladek and Nawy, 2020).